CTRI/2018/08/015262
Completed
Phase 4
An Open labeled phase IV clinical trial to assess the safety and tolerability of Ebastine (10 mg) and Phenylephrine (10 mg) FDC as short duration therapy, in patients with allergic rhinitis
Sterling Lab0 sites145 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sterling Lab
- Enrollment
- 145
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnosis of mild and moderate\-severe intermittent allergic rhinitis ( \<\= 4 days per week AND \<\= 4 weeks)
- •2\. Able to provide informed consent to participate in the study
- •3\. Ability to understand study procedures and to comply with them for the entire length of the study including able to record symptom scores in a diary (literate patients).
- •4\. TSS baseline score of at least 5 both on screening and randomization day (based on investigator assessment)
- •5\. Treatment naive for current episode of allergic rhinitis \[if patient has already consumed any medication for the current episode, then a wash\-out of about 6\-7 days to be given before administering study medication
Exclusion Criteria
- •1\. Asthma patients
- •2\. Subjects with a current history of frequent, clinically significant sinusitis or chronic purulent postnasal drip.
- •3\. Subjects who, in the opinion of the investigator, are dependent on nasal, oral or ocular decongestants, nasal topical antihistamines or nasal steroids.
- •4\. Any illness requiring steroid by any route.
- •5\. Urticaria, Vasomotor rhinitis, Rhinitis medicamentosa.
- •6\. Subjects who have, in the opinion of the investigator or designee, clinically significant nasal structural abnormalities, including large nasal polyps or marked septum deviation, that significantly interferes with nasal air flow.
- •7\. Pregnancy or lactation.
- •8\. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- •9\. Use of any other investigational drug in the last 90 days.
- •10\. Subjects known to have an idiosyncratic reaction to any of the ingredients in IMP
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved despite regular use of tear substitutes before and after Exposure to an Adverse Controlled EnvironmentEUCTR2019-000982-19-ESInstituto de Oftalmobiología Aplicada (IOBA)25
Recruiting
Phase 4
A open label, phase IV clinical trial examining the efficacy of Prothrombinex alone verses Prothrombinex combined with fresh frozen plasma in patients who require Warfarin reversal.The efficacy to reverse the effect of warfarin by prothrombinex aloneBlood - Clotting disordersACTRN12607000567426Frankston Hospital40
Active, not recruiting
Not Applicable
An open-label, phase IV, pilot study, to evaluate confocal microscopic findings of cornea, ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switching from latanoprost 0.005% (preserved) to preservative free tafluprost 0.0015% eye drops.EUCTR2010-021039-14-FITampere University, Faculty of Medicine, Department of Ophthalmology30
Not yet recruiting
Phase 4
A clinical trial to study the effect of herbal hair treatment on hair lossCTRI/2020/04/024543Allen Laboratories Limited
Active, not recruiting
Phase 1
An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapyEUCTR2019-000817-35-GBAlmirall250